Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma

Published:April 23, 2021DOI:
      Xeroderma pigmentosum (XP) is an autosomal recessive disorder characterised by deficient nucleotide excision repair (NER) of ultraviolet-induced DNA damage resulting in an increased skin carcinogenesis [
      • Lehmann A.R.
      • et al.
      Xeroderma pigmentosum.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lehmann A.R.
        • et al.
        Xeroderma pigmentosum.
        Orphanet J Rare Dis. 2011; 6: 70
        • Deinlein T.
        • et al.
        Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature.
        Eur J Canc. 2017; 83: 99-102
        • Hauschild A.
        • et al.
        Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
        Eur J Canc. 2017; 77: 84-87
        • Momen S.
        • et al.
        Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
        Cold Spring Harb Mol Case Stud. 2019; 5
        • Hong W.J.
        • et al.
        Angiosarcoma arising on the scalp in a Korean patient with xeroderma pigmentosum variant type.
        Photodermatol Photoimmunol Photomed. 2018; 34: 343-346
        • De Silva B.D.
        • et al.
        Angiosarcoma of the head and neck associated with xeroderma pigmentosum variant.
        Br J Dermatol. 1999; 141: 166-167
        • D'Angelo S.P.
        • et al.
        A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401).
        Lancet Oncol. 2018; 19: 416-426
        • Mehnert J.M.
        • et al.
        Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
        J Clin Invest. 2016; 126: 2334-2340
        • Soura E.
        • et al.
        Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
        Pediatr Dermatol. 2018; 35: e334-e336